TEVA PHARMACEUTICAL INDUSTRIES LIMITED |
Market Closed -
Other stock markets
|
After market 12:24:09 | |||
| 13.82 USD | -1.25% |
|
13.98 | +1.08% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 15.86B 21.66B | Sales 2025 * | 16.4B 22.4B | Capitalization | 15.83B 21.63B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.54B 2.1B | Net income 2025 * | 1.44B 1.97B | EV / Sales 2024 * | 1.93 x |
| Net Debt 2024 * | 14.82B 20.24B | Net Debt 2025 * | 12.25B 16.73B | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
11.2
x | P/E ratio 2025 * |
10.5
x | Employees | 35,737 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teva Pharmaceutical Industries Limited
More recommendations
More press releases
More news
| 1 day | +1.23% | ||
| 1 week | +0.87% | ||
| Current month | -0.25% | ||
| 1 month | -1.44% | ||
| 3 months | +14.32% | ||
| 6 months | +54.56% | ||
| Current year | +34.64% |
1 week
13.72
14.18
1 month
12.4914.40
Current year
10.4514.41
1 year
7.1014.41
3 years
6.8214.41
5 years
6.1414.51
10 years
6.1425.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 14.05 | -0.08% | 7,592 |
| 24-05-02 | 14.06 | +1.29% | 608,816 |
| 24-05-01 | 13.88 | -1.45% | 12,887 |
| 24-04-30 | 14.08 | -0.81% | 13,718 |
| 24-04-29 | 14.2 | +1.95% | 11,135 |
Delayed Quote London S.E., May 03, 2024 at 11:30 am
More quotes
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.98
USD
Average target price
15.74
USD
Spread / Average Target
+12.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.50% | 662B | |
| +22.23% | 546B | |
| -4.93% | 359B | |
| +16.97% | 323B | |
| +4.08% | 289B | |
| +13.68% | 234B | |
| +3.84% | 198B | |
| -10.35% | 194B | |
| +3.98% | 167B |
- Stock Market
- Equities
- TEVA Stock
- 0LER Stock